Lene Gerlach

Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.

Chromologics is a Danish biotech start-up responding to the strong market pull for novel natural food colorants. We develop fungal fermentation solutions for the production of natural pigments. Our proprietary production process allows not only for a more sustainable production than existing solutions, but is also cost-competitive. Our pigments are produced by a non-GMO fungus, which makes them compliant with the dietary requirements of broad consumer bases such as kosher, halal, and vegan diets.

Pioneering new sustainable bio-based ingredients

Copenhagen Nanosystems (cphnano.com) is a Danish Labtech company that develops solutions for particle size analysis and UV-Vis spectroscopy. We work with upgrading UV-Vis spectrophotometry across all brands to be at the forefront at the technology development. We expand the functionality of existing spectrophotometers by developing plastic labware with nanotechnology and analyzing data in the cloud - leading to faster and more accurate results in the laboratory while lowering upfront investments. The NanoCuvettes™ unlocks the full potential of the spectrophotometer and SpectroWorks™ optimizes and automizes your UV-Vis instrument workflow.

Cerebriu’s proven radiology AI solutions detect findings during the initial scan and enable the most appropriate procedures while the patient is still in the scanner. This leads to a simpler, faster MR image acquisition and creates tangible clinical value: Improving technologists’ confidence and freeing up radiologists’ time by ensuring the right data the first time the patient is in the scanner Timely diagnosis of critical findings by prioritizing radiologists’ worklists Improving patient experience and reducing patient recalls

At VentriJect, we want to change how we work with cardiorespiratory fitness. Cardiorespiratory fitness, also expressed as VO2max, is the strongest indicator of health, according to several studies, and even small improvements in VO2max can mean a significant health improvement. Unfortunately, evaluating cardiorespiratory fitness today can be cumbersome, time-consuming, expensive and dependent on highly-trained staff. At VentriJect we want to change that. Introducing the Seismofit - a radical new approach to evaluating cardiorespiratory fitness. With high accuracy, no training required, and extreme ease of use, we can estimate your VO2max in less than 3 minutes - a fraction of the time used with other approaches. This clinical-validated and patented technology is unique and a true game-changer, and will provide significant value to the patients and the healthcare practitioners. VentriJect was established as a spin-out from a leading research center in cardiology at Aalborg University in 2018 and is situated in Hellerup near Copenhagen, Denmark.

Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism. Antag’s lead molecule AT-7687 is specifically designed to target and deactivate the GIP receptor, a genetically-validated pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction – and is mechanistically distinct from GLP-1 therapies. Antag’s GIPR antagonist approach stems from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, two co-founders of the business. Antag’s vision is that all people living with obesity, diabetes and overweight have a personal treatment option that goes beyond weight loss to improve long-term health, without having to compromise on tolerability.

MedTrace is striving to minimize diagnostic uncertainty through better perfusion imaging. Perfusion imaging provides medical professionals with a functional understanding of the organs blood supply inside the patient. MedTrace is developing a solution that will help healthcare providers diagnose patients more accurately and quickly. Our solution allows for absolute blood flow quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for non-invasive blood flow quantification. Our innovative solution is intended to making 15O-water practically available right next to the PET scanner connected to an onsite cyclotron, with a software package to quantify the myocardial blood flow and perfusion. IMPORTANT NOTICE: MedTrace’s products are not currently cleared for routine use in any markets, including both the US and Europe. In the US, 15O-water is currently under investigation as an investigational drug in a Phase 3 clinical trial. In Europe, its use is in compliance with approvals granted by national drug authorities, in accordance with the specific legislation of each member state.

Creating Employer Brand that people dream of working for.

Airofit is a Danish developed training system, tailored to athletes who expect more from their performance. The original device was created for asthma and COPD patients. Since then, the breathing trainer has been developed to improve the breathing of athletes and be a tool to assist the athlete in his or her ambition for greatness. So, how does it work? The Airofit device is connected to an app that measures your results and improvements after each breathing session. In the app, there are multiple programs which all focus on different areas of your breathing. Each session results in a different benefit that takes you to a higher level of performance. Having different training programs gives you the freedom to improve and focus on the areas, that are the most important for you. The goal is to train your respiratory system overall, as having a thorough knowledge of how this works and obtaining a powerful breathing helps your overall performance.

Hoba Therapeutics is a Danish biotech developing restorative treatments for chronic pain disorders and hearing loss. Both indications have a clear unmet medical need for safe and efficacious treatments for millions of patients worldwide. Hoba Therapeutics is developing HB-086 for the treatment of chronic neuropathic pain. HB-086 is a non-opioid compound with a unique mechanism of action targeting the peripheral nervous system to reverse neuropathic pain and the underlying cause of the disease. The second drug candidate HB-097 is a pharmacological treatment for sensorineural hearing loss. Preclinical data of HB-097 show both a preventive effect of hearing loss by protecting nerve cells and a regenerative effect by reversal of already induced damage. Hoba Therapeutics was founded in 2016 by Novo Holdings and Borean Innovation. Hoba Therapeutics received the Accelerator grant from the European Innovation Council in 2021 and the Grand Solution grant from Innovation Fund Denmark in 2018. About chronic neuropathic pain: Chronic neuropathic pain is a significant global health issue, affecting a substantial portion of the population worldwide. In Europe, the prevalence is estimated to be 6–8% of the general population. Chronic neuropathic pain represents an enormous personal and economic burden. Neuropathic pain is a chronic disorder resulting from damage or dysfunction of the nervous system. Causative factors are lesions in or disorders of the nervous system, such as injury, pressure, toxic agents (e.g., chemotherapy), viral infections, and metabolic disorders. These lesions lead to aberrant functioning of sensory nerve cells, resulting in a chronic, debilitating sensation of pain. The complexity and variability of chronic neuropathic pain necessitates a multifaceted treatment approach and highlights the need for a more effective and safer treatment options. The global neuropathic pain market is estimated to be valued at USD 7.6 bn.

Cbio A/S is a biopharmaceutical company developing next generation T-cell therapies against solid tumors. We are soon to enter our First-in-Human clinical study at Karolinska Hospital in Sweden with our proprietary T-cell product, novoleucel, where the T-cell are armed against oxidative stress. We are located in Copenhagen, Denmark in a 1,000 m2 state-of-the-art facility where we develop and produce cell-based therapy products for clinical use.

Invest In Equity is an international force accelerating gender equity to redefine the future of life science investment. By elevating women in investment roles, we’re not just addressing imbalance, we’re building a more resilient, innovative, and impactful investment ecosystem. We unite the investors and industry influencers who recognise that inclusive investment leadership fuels stronger returns and enduring impact. Join our network of investors, leaders and innovators steering the future of life science investment. Because equity isn’t just financial, it’s foundational. Investing in tomorrow’s breakthroughs? Invest in Equity, today. #InvestInEquity #GenderEquity #Investment #LifeSciences

At SCHMIDT Capital Advisors, our mission is to offer corporate finance advisory services that are not just technically excellent but enriched by decades of experience from our own careers as senior executives and board members in growth companies. We provide broad-based financial and strategic advice grounded in decades of experience from all sides of the table. The members of our Special Advisor group have at various points in their careers been corporate finance advisors, CEOs, board members, VC investors, underwriters, or IR executives across numerous growth companies. We are life science experts but otherwise industry-agnostic. With Schmidt Capital Advisors, you’ll be advised by people who know what it is like to lead growth companies and have managed enough transactions to understand the pitfalls. Our advisory offering includes IPOs, Directed Issues, Rights Issues, Uplistings, Private placements, and M&A assignments. We work with main market listed companies as well as companies listed on First North, Spotlight and NGM.

Hadean Ventures is a European life science fund manager with a particular focus on the Nordic region. Hadean Ventures invests broadly across the life science sector, including in speciality pharmaceuticals, medical technology, diagnostics and digital health. Hadean Ventures has offices in Oslo and Stockholm.

Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality. Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient. SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.